Studies over the last decade have demonstrated that some polycystic ovary syndrome (PCOS) patients have abnormal insulin sensitivity (insulin resistance), independently from being overweight or obese. This induces the risk of developing type 2 diabetes in such PCOS patients. The use of insulin sensitizers (i.e. metformin), reduces such metabolic, and most hormonal, impairments. As metformin often induces side effects, new integrative strategies have been proposed to treat insulin resistance, such as the use of inositols. Such compounds are mainly represented in humans by two inositol stereoisomers: myo-inositol (MYO) and d-chiro-inositol (DCI). MYO is the precursor of inositol triphosphate, a second messenger that regulates thyroid-stimulating hormone (TSH) and FSH as well as insulin. DCI derives from the conversion of myo-inositol via an insulin-dependent pathway. Several preliminary studies have indicated possible benefits of inositol therapy in PCOS patients, but to date no meta-analysis has been performed. This review aims to give clinical insights for the clinical use of inositol in PCOS.

Inositol as putative integrative treatment for PCOS / Genazzani, Alessandro. - In: REPRODUCTIVE BIOMEDICINE ONLINE. - ISSN 1472-6483. - ELETTRONICO. - 33:6(2016), pp. 770-780. [10.1016/j.rbmo.2016.08.024]

Inositol as putative integrative treatment for PCOS

GENAZZANI, Alessandro
2016

Abstract

Studies over the last decade have demonstrated that some polycystic ovary syndrome (PCOS) patients have abnormal insulin sensitivity (insulin resistance), independently from being overweight or obese. This induces the risk of developing type 2 diabetes in such PCOS patients. The use of insulin sensitizers (i.e. metformin), reduces such metabolic, and most hormonal, impairments. As metformin often induces side effects, new integrative strategies have been proposed to treat insulin resistance, such as the use of inositols. Such compounds are mainly represented in humans by two inositol stereoisomers: myo-inositol (MYO) and d-chiro-inositol (DCI). MYO is the precursor of inositol triphosphate, a second messenger that regulates thyroid-stimulating hormone (TSH) and FSH as well as insulin. DCI derives from the conversion of myo-inositol via an insulin-dependent pathway. Several preliminary studies have indicated possible benefits of inositol therapy in PCOS patients, but to date no meta-analysis has been performed. This review aims to give clinical insights for the clinical use of inositol in PCOS.
2016
16-set-2016
33
6
770
780
Inositol as putative integrative treatment for PCOS / Genazzani, Alessandro. - In: REPRODUCTIVE BIOMEDICINE ONLINE. - ISSN 1472-6483. - ELETTRONICO. - 33:6(2016), pp. 770-780. [10.1016/j.rbmo.2016.08.024]
Genazzani, Alessandro
File in questo prodotto:
File Dimensione Formato  
Reprod BioMed Online 2016 - Inositol review.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 979.33 kB
Formato Adobe PDF
979.33 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
VOR_Inositol as putative integrative treatmentfor PCOS.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 989.96 kB
Formato Adobe PDF
989.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1110882
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 59
social impact